Core Viewpoint - China Resources Pharmaceutical (03320) reported Tianshili Pharmaceutical's performance for the first half of 2025, showing a slight decline in total revenue but an increase in net profit attributable to shareholders [1] Financial Performance - Total revenue for the first half of 2025 was approximately 4.288 billion yuan, representing a year-on-year decrease of 1.91% [1] - Net profit attributable to shareholders was about 775 million yuan, reflecting a year-on-year increase of 16.97% [1] - Basic earnings per share were reported at 0.52 yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公 告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 天士力醫藥集團股份有限公司（「天士力醫藥」）為一家於中華人民共和國註冊 成立的公司。天士力醫藥的股份於上海證券交易所上市。截至本公告日期，天 士力醫藥由華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集 團」）通過其非全資附屬公司華潤三九醫藥股份有限公司持有約28%的權益，並 以本公司附屬公司的形式入賬。 1 於2025年8月15日，天士力醫藥公佈其截至2025年6月30日止六個月的半年度報 告（「天士力醫藥未經審核財務資料」）。下表載列天士力醫藥未經審核財務資 料的主要財務資料： | | 截至6月30日止六個月 | | 增加╱減少 | | --- | --- | --- | --- | | | 2025 | 2024 | | | | （人民幣） | （人民幣） | (%) | | | （未經審核） | （未經審核） | | | 營 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 | | 截至 | 截至 | | | --- | --- | --- | --- | | | 2025年6月30日 | 2024年12月31日 | 增加╱減少 | | | （人民幣） | （人民幣） | (%) | | | （未經審核） | （經審核） | | | 總資產 | 12,657,788,827.12 | 12,611,367,133.57 | 0.37% | | 上市公司股東應佔資產 | 5,226,959,645.61 | 5,253,648,545.41 | –0.51% | | | 截至6月30日止六個月 | | | | | 2025年 | 2024年 | 增加╱減少 | | --- | --- | --- | --- | | | （人民幣） | （人民幣） | (%) | | | （未經審核） | （未經審核） | | | ...

Core Viewpoint - China Resources Pharmaceutical (03320) announced plans to establish a fund with an expected scale of 500 million yuan, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [2][2]. Company Summary - The fund will involve China Resources Pharmaceutical (Shantou), China Resources Double Crane, Double Crane (Beijing), and China Resources Pharmaceutical Investment, along with Hanwei Huayou Shantou and other interested partners [2][2]. - China Resources Pharmaceutical plans to commit a total investment of no more than 123 million yuan, accounting for approximately 24.6% of the total committed capital of the fund [2][2]. - The fund is expected to be managed by Shenzhen China Resources Capital and will not be accounted as a subsidiary of China Resources Pharmaceutical upon establishment [2][2]. Related Parties - Hanwei Huayou Shantou is a wholly-owned subsidiary of China Resources Investment (Tianjin), which is ultimately held by China Resources Group, the controlling shareholder of China Resources Pharmaceutical, thus constituting a related party transaction [2][2]. Business Overview - Established in 2007, China Resources Pharmaceutical operates in the manufacturing and commercial distribution of pharmaceuticals, health products, and medical devices [2][2]. - The company owns several subsidiaries, including China Resources Pharmaceutical Commercial Group Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double Crane Pharmaceutical Co., Ltd., China Resources Jiangzhong Pharmaceutical Group Co., Ltd., and Dong'e Ejiao Co., Ltd. [2][2]. Financial Performance - In 2024, China Resources Pharmaceutical achieved operating revenue of 257.673 billion yuan, representing a year-on-year growth of 5.3% [2][2]. - The net profit attributable to the parent company was 3.351 billion yuan, showing a year-on-year decline of 13.06% [2][2].

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total committed capital for the fund [1] Group 2 - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Major Events - Kangji Medical (09997) received a privatization offer at a premium of approximately 9.9% [1] - China Resources Pharmaceutical (03320) plans to participate in the establishment of a fund [1] - Ganfeng Lithium (01772) intends to jointly integrate a joint venture with LAR to develop the Pozuelos-Pastos Grandes salt lake basin in Argentina [1] - China Antibody-B (03681) signed a comprehensive strategic cooperation agreement with the Hong Kong Advanced Institute of Research at Sun Yat-sen University [1] - Mingyuan Cloud (00909) plans to acquire 100% equity of ASIOT Corporation for 700 million yen [1] - Weilu Group (01196) experienced unusual stock price and trading volume changes and is in preliminary discussions with an independent third party regarding a potential acquisition of mobile game rights [1] Operating Performance - China Unicom (00762) reported revenue exceeding 200 billion yuan in the first half of the year, with a profit attributable to equity holders of 14.484 billion yuan, a year-on-year increase of 5.01% [1] - China Unicom (00762) had approximately 1.208 billion cumulative "Ubiquitous Intelligent Connection" users in the second quarter [1] - Tencent Music (01698) achieved double growth in revenue and profit in the first half of the year, with a profit attributable to equity holders of 6.7 billion yuan, a year-on-year increase of 115.85% [1] - Galaxy Entertainment (00027) reported a mid-term profit attributable to shareholders of 5.24 billion HKD, a year-on-year increase of 19.44% [1] - WH Group (00288) reported a mid-term profit attributable to shareholders of 788 million USD, a year-on-year increase of 0.51%, with an interim dividend of 0.2 HKD per share [1] - Minmetals Resources (01208) reported a mid-term profit attributable to equity holders of 340 million USD, a year-on-year increase of 1511% [1] - China Literature Group (00772) reported a mid-term profit attributable to shareholders of 850 million yuan, a year-on-year increase of 68.5% [1] - Hong Kong Electric (02638) reported a mid-term profit attributable to unit holders of 1.001 billion HKD, a year-on-year increase of 5.7% [1] - 361 Degrees (01361) reported a mid-term profit attributable to equity holders of 858 million yuan, a year-on-year increase of 8.6% [1] - Eagle Precision (01286) reported a mid-term profit attributable to equity holders of 346 million HKD, a year-on-year increase of 13.7% [1] - China Everbright Water (01857) reported a mid-term profit attributable to equity holders of 564 million HKD, a year-on-year decrease of 2.99% [1] - FIT HON TENG (06088) reported a mid-term profit attributable to shareholders of 31.511 million USD, a year-on-year decrease of 3.11% [1] - China Lilang (01234) reported a mid-term profit attributable to equity holders of 243 million yuan, a year-on-year decrease of 13.4% [1] - Fudan Zhangjiang (01349) reported a mid-term profit attributable to shareholders of 5.715 million yuan, a year-on-year decrease of 91.89% [1] - Wharf Holdings (00004) reported a mid-term profit attributable to shareholders of 535 million HKD, returning to profitability [1] - China Resources Land (01109) reported a cumulative contract sales amount of approximately 123.6 billion yuan for the first seven months, a year-on-year decrease of 11.8% [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration with its subsidiaries and Hanwei Huayou Shantou to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - The fund is expected not to be accounted as a subsidiary of the company upon establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Group 1 - The core announcement involves China Resources Pharmaceutical (03320.HK) planning to establish a fund with an expected scale of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology [1] - The company intends to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager after its establishment [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於香港註冊成立的有限公司） （股份代號：3320） 內幕消息 擬議成立基金暨關連交易 本公告乃由本公司根據上市規則第13.09(2)條及《證券及期貨條例》（香港法 例第571章）第XIVA部內幕消息條文作出。 華潤醫藥（汕頭）、華潤雙鶴、雙鶴（北京）、華潤醫藥投資（各自為本公司之附 屬公司）與漢威華酉汕頭及其他有意合夥人就成立預期規模為人民幣5億元 之基金進行協商。基金預期主要從事合成生物學、創新藥物及生物技術領域 的高增長企業投資。本集團擬承諾出資總額預期為不高於人民幣1.23億元， 約佔基金承諾出資總額的24.6%。預期基金於成立後將不會入賬為本公司之 附屬公司。預期深圳華潤資本將獲委託為基金之基金管理人。 1 於本公告之日，一名擬議合夥人漢威華酉汕頭為華潤投資（天津）的全資附 屬公司，而華潤投資（天津）由本公司控股股東華潤集團最終持有。因此，漢 威華酉汕頭構成了本公司的關連人士，而有限合夥協議 ...